TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel

Go back to TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel

TherapeuticsMD Announces First Quarter 2021 Financial Results

May 6, 2021 7:00 AM EDT

- 1Q21 total net revenue increased to $19.9 million -

- 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 -

- ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance -

- Further strengthened ANNOVERA® patent family through June 2039

- Significantly improved average net revenue per unit for IMVEXXY® to $61 and BIJUVA® to $69 -

-vitaCares divesture process continues in an effort to unlock shareholder value-

- Conference call scheduled... More